Immuno oncology News and Research

RSS

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), in a poster session at the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana, December 12-15, 2026.

5 Nov 2026

Scientists discover immune pathway behind radiation-induced lung damage

Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, have uncovered an immune pathway that may contribute to radiation-related lung damage and have identified a potential strategy to block it.

20 Oct 2026

First patient dosed in Phase 1 clinical trial of new cancer drug

On August 18, 2026, in Japan, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital, led by Professor Toshio SHIMIZU, administered DS1025 to the first patient worldwide as part of a global, multicenter First-in-Human Phase 1 clinical trial sponsored by Daiichi Sankyo.

19 Oct 2026

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal

invIOs GmbH (“invIOs”), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular Therapy Oncology.

16 Oct 2026

Rare dendritic cells may promote immune tolerance in metastatic cancer

This study was co-led by Steven Blum, MD. Gary Reynolds, MD, PhD, Samuel Klempner, MD, and Alexandra-Chloé Villani, PhD, jointly supervised the work at the Krantz Family Center for Cancer Research within the Mass General Brigham Cancer Institute and the Mass General Brigham Center for Immunology & Inflammatory Diseases (CIID).

8 Oct 2026

Dr. GPCR and Eurofins Discovery join forces to advance GPCR drug discovery

Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, today announced a strategic partnership with Eurofins Discovery, the drug discovery services side of the same group behind the Eurofins DiscoverX products many in the community already know.

From Eurofins Discovery 5 Oct 2026

Laverock Therapeutics announces in vivo programs in oncology and genetic medicine

Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announces its in vivo programs spanning CAR-T and genetic medicine

From Laverock Therapeutics 30 Sep 2026

Existing anti-seizure drug slows the growth of diffuse midline gliomas

An existing anti-seizure drug slows the growth of a devastating group of childhood cancers, new Stanford Medicine-led research has shown.

17 Sep 2026

ACROBiosystems deepens its France presence with a dedicated hub at The HIVE Innovation Center, embedding into the Campus Grand Parc ecosystem

Kadans Science Partner is pleased to welcome ACROBiosystems to The HIVE Innovation Center, its laboratory and office building dedicated to the life sciences, situated on the Campus Grand Parc in Villejuif.

From ACROBiosystems 16 Sep 2026

Vitamin A derivative prevents immune cell exhaustion in brain tumors

Immune cells can become exhausted after prolonged exposure to cancer, gradually losing their ability to attack tumor cells.

8 Sep 2026

Gene removal makes engineered immune cells more effective against osteosarcoma

Scientists at St. Jude Children's Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed osteosarcoma.

25 Aug 2026

UC Irvine researchers develop framework to make CAR T-cell therapy safer

CAR T-cell therapy has transformed cancer care, offering new hope to patients with aggressive blood cancers who once had few treatment options.

18 Aug 2026

Blocking ZFP36L2 protein may disrupt colorectal cancer metastatic growth

Digestion is hard on the cells that line the human gut, and they are constantly being shed and replaced. This renewal is driven by a population of tireless stem cells.

5 Aug 2026

New strategy combines cancer immunotherapy and gene therapy in a single nanoparticle

Cancer cells survive by hiding from the immune system's surveillance. A KAIST research team has developed a new anticancer platform that makes cancer cells send out their own danger signal—prompting immune cells to attack—while simultaneously delivering gene therapy.

28 Jul 2026

UVA researchers develop a new experimental approach to target glioblastoma

University of Virginia Comprehensive Cancer Center scientists have developed a promising new experimental approach to targeting glioblastoma, the most common and deadliest brain cancer.

22 Jul 2026

New cell culture method allows targeted study of antibody regulation

For the immune system to effectively combat pathogens, antibody responses must be precisely controlled. So-called follicular regulatory T cells (Tfr cells) play a key role in this process by limiting excessive immune responses and helping to maintain immune tolerance.

25 Jun 2026

Breast milk nutrient boosts long-term immune system development

Trans-vaccenic acid (TVA), the most abundant trans fatty acid found in human breast milk, helps boost immune system development and has long-lasting effects on immune system health in mice, according to a new study by researchers from the University of Chicago.

18 Jun 2026

New genetic tool tracks how bacteria spread between people

The research, published on April 24th, 2026, in Nature Microbiology, describes how the new tool, called TRAnsmision Clustering of Strains (TRACS), uses genomics to distinguish between closely related bacterial strains.

4 May 2026

Cryo-expansion microscopy reveals three-dimensional organization of killer T cells

Cytotoxic T lymphocytes are the body's specialized "killer" cells, precisely eliminating infected or cancerous cells.

29 Apr 2026

Scientists link poor sleep to decreased chemotherapy response via the gut

Sleep deprivation has long been known to weaken the immune system. Now UF Health Cancer Institute researchers have made a startling discovery: The gut microbiota drives changes to the immune system caused by chronic sleep loss. These changes promote cancer progression, disrupt circadian rhythm and weaken the effectiveness of chemotherapy.

17 Apr 2026